Common questions about Omnipaque 350 (FAQ)
Q: What are the most common side effects that patients actually experience?
Official product information states that the most frequently documented adverse reactions are generally related to the contrast administration. These commonly reported effects include a sensation of heat or flushing, headache, dizziness, nausea, and vomiting.
Q: Is it true that Omnipaque 350 can cause a metallic taste or warm feeling?
Regulatory documents note that the sensation of heat or flushing is a common effect. Additionally, a temporary taste perversion—meaning a change in taste or an unpleasant taste, such as a metallic taste—has been reported as a less common adverse reaction.
Q: How long does the warm or 'flushing' sensation last after the Omnipaque injection?
Official documents describe this warm or flushing sensation as being a common side effect but note that the effects are generally mild and of short duration.
Q: Why are people with pre-existing kidney problems at a higher risk with contrast agents?
Patients with pre-existing kidney conditions may have an increased risk of developing Acute Kidney Injury (AKI), which is the sudden worsening of kidney function. Official guidance emphasizes that adequate hydration is important to help reduce this risk.
Q: Do I need to stop taking my Metformin before receiving Omnipaque 350?
Regulatory labeling places a timing restriction on the use of Metformin. Official labeling states that the medication must be stopped at the time of or before the injection. It should not be resumed until at least 48 hours after the procedure and only after renal function has been reevaluated.
Q: Can Omnipaque 350 affect my thyroid gland or thyroid test results?
The iodine in Omnipaque 350 is noted to potentially interfere with the diagnostic or therapeutic effects of Radioactive Iodine (I^131 and I^123) procedures. Additionally, official safety notes address a documented risk of thyroid dysfunction in pediatric patients aged 0 to 3 years, requiring specific monitoring.
Q: How long does Omnipaque 350 stay in the body, and how is it eliminated?
The contrast medium is primarily excreted unchanged from the body by the kidneys. Official pharmacokinetic data indicates that the elimination half-life of the contrast medium is variable and depends on the patient's kidney function.
Q: Is it true that anxiety or stress can increase the chance of having a reaction to the contrast?
Official information suggests that individuals with high levels of anxiety may have an elevated risk of experiencing certain adverse reactions to the contrast medium.
Q: What signs of an allergic reaction should I watch for after leaving the hospital?
Although the most severe reactions tend to occur quickly, regulatory information notes that delayed reactions can develop hours or even weeks later. Potential delayed signs to be aware of include rash, hives (urticaria), itching (pruritus), or difficulty breathing (dyspnea). Rare, severe skin reactions have been reported to develop between one hour and several weeks after administration.
Q: Can Omnipaque 350 be safely used while breastfeeding?
Official documents state that lactating women should pump and discard breast milk for 10 hours following the procedure to minimize infant exposure. Studies indicate that Iohexol is present in milk at low levels and is poorly absorbed by the infant's digestive system.
Q: What is the main difference between Omnipaque 350 and other contrast dyes for a CT scan?
Omnipaque 350 (iohexol) is classified as a non-ionic, low-osmolar contrast agent (LOCA), which is known for having physiological compatibility close to that of blood plasma. Reports suggest that this agent has been associated with a favorable incidence of acute adverse reactions when compared with some other low-osmolar contrast media.
Q: How long after taking Omnipaque 350 oral solution can I expect to have bowel movements?
Official product labeling does not define a specific timeframe for bowel movement onset after taking the oral solution. However, oral administration is frequently associated with mild, transient diarrhea.
Q: Does drinking extra water help get Omnipaque 350 out of my system faster?
Regulatory guidance emphasizes that ensuring adequate hydration is crucial both before and after administration of the contrast agent. This measure is intended to help ensure the contrast medium is properly cleared by the kidneys as part of the natural elimination process.
Q: Does having a shellfish allergy mean I am allergic to Omnipaque 350?
Official information and major clinical consensus indicate that a history of shellfish allergy is not associated with a specific increased risk of adverse reactions to iodinated contrast media such as Omnipaque 350. The risk of reaction due to shellfish allergy is generally not considered higher than the risk associated with other unrelated allergies.
Q: Are there any specific concerns about Omnipaque 350 use in elderly patients?
Official labeling notes that older adult patients may have an increased susceptibility to adverse events. This is due to the greater frequency of decreased renal, hepatic, or cardiac function observed in this population.
Q: Why would a doctor use Omnipaque 350 specifically for an X-ray of the spinal cord (myelography)?
It is important to know that the specific Omnipaque 350 mgI/mL concentration is not approved for direct injection into the spinal fluid (intrathecal use) and carries a severe safety restriction for this route. While the active ingredient, iohexol, is indicated for myelography, only specific, lower concentrations are approved for that use.
Q: Can the injection of Omnipaque 350 cause temporary pain or discomfort at the injection site?
Regulatory documents state that a mild sensation of warmth or pain at the site is the most frequent effect reported during the injection. Official labeling also warns that extravasation—the leakage of the medium outside the vein—can occur and may cause pain, redness, or swelling.
Q: Can Omnipaque 350 affect a person's blood pressure?
Official reports indicate that changes in blood pressure have occurred following administration. Both hypotension (low blood pressure) and an increase in blood pressure have been noted as potential side effects, with severe reactions occasionally leading to cardiovascular events.
Q: What is a 'contrast reaction' versus a true allergy to the dye?
Adverse reactions to contrast media are often popularly, but inaccurately, referred to as 'allergies.' Most of these events are classified as idiosyncratic or pseudoallergic reactions because they are typically not mediated by the immune system (not true allergies) but rather by other biological mechanisms.
Q: Can Omnipaque 350 cause dizziness or confusion after the procedure?
Dizziness is listed in the official safety information as a commonly documented adverse reaction. Confusion is also noted among the reported side effects, though it is considered a less common occurrence.
Q: Is there a maximum number of times I can receive Omnipaque 350 in a year?
Official documents do not define a specific maximum number of times the drug can be received in a year. Regulatory guidance only recommends a suitable time interval—suggesting at least 48 hours—between sequential or repeat examinations to allow the body to clear the contrast medium.
Q: Does Omnipaque 350 increase the risk of a sickle cell crisis in affected patients?
Official documentation lists Sickle Cell Anemia as a condition where caution is required during administration. The contrast agent is noted to potentially worsen the condition in affected patients.
Q: Can this contrast agent interfere with other laboratory or blood tests?
The iodine in Omnipaque 350 can temporarily affect certain laboratory values. Specifically, the iodine can increase protein-bound iodine in the blood, and regulatory guidance suggests that the protein-bound iodine test should not be performed for at least 16 days following administration.
Q: Can Omnipaque 350 cause a temporary change in vision?
Vision abnormalities are listed in official documents as potential adverse reactions following injection. These abnormalities have included blurred vision and temporary vision loss.
Q: Are there any specific precautions for children receiving Omnipaque 350?
While use is allowed in pediatric patients, official warnings include the need for thyroid function monitoring in children 0 to 3 years of age. Caution may also be required for children with pre-existing conditions such as asthma, heart failure, or kidney problems.
Q: How quickly does the Omnipaque 350 show up on the scan after injection?
The contrast agent is often administered as a rapid bolus injection into a vein or artery to achieve visualization quickly. This is done to facilitate immediate visualization of structures, such as during arterial imaging, meaning the contrast effect is near-instantaneous once it reaches the target area.
Q: If I had a reaction to a contrast dye a long time ago, will I definitely react to Omnipaque 350?
Official safety information indicates that patients with a history of a previous reaction to any contrast agent, or those with known allergic disorders, have an increased risk of having a hypersensitivity reaction. However, this increased risk does not guarantee a future reaction.
Q: Can Omnipaque 350 cause hair loss or skin peeling in rare cases?
Some less common side effects have been reported. Hair loss has been noted, particularly related to the risk of hypothyroidism in young children. Additionally, rare, severe skin reactions, which can involve blistering, peeling, or loosening of the skin (known as SCAR), have been reported.
Q: Can Omnipaque 350 be given if I have a history of epilepsy or seizures?
Regulatory documents indicate that patients with a history of epilepsy or seizures may be at an increased risk for adverse events. The contrast medium is noted to potentially increase the risk of seizures, and specific neurological precautions are required during administration.
Q: Is it true that a small amount of Omnipaque can leak out of the vein (extravasation)?
The official labeling warns that extravasation (the leakage of the contrast medium outside the vein) can occur during intravascular injection. In rare cases, this event may potentially cause serious complications, such as tissue necrosis or compartment syndrome.
Q: What volume or amount of Omnipaque 350 is typically used in a standard procedure?
Official product labeling shows that the volume of Omnipaque 350 administered is highly dependent on the patient's characteristics and the specific imaging procedure being performed. Volumes can vary widely, with examples ranging from 30 to 60 mL for procedures like ventriculography.
Q: Is Omnipaque 350 the only type of iohexol contrast available?
No, Omnipaque 350 is one of several available formulations. The active ingredient, iohexol, is manufactured under the Omnipaque brand in multiple concentrations of iodine, including 140, 180, 240, and 300 mgI/mL, depending on the diagnostic need.
Q: Do specific medical conditions (like thyroid storm or pheochromocytoma) require special precautions with Omnipaque 350?
Official documentation lists Pheochromocytoma—a tumor of the adrenal glands—as a condition where administration should proceed with caution. The contrast agent may potentially worsen this underlying condition.
